Yuseong gu, South Korea
Yuseong gu, South Korea

Time filter

Source Type

Patent
Intelligent Synthetic Biology Center | Date: 2016-06-27

Provided are a food composition and a feed composition for removing amyloid plaques, each composition including ginsenoside F1, in which ginsenoside F1 is effective for removing amyloid plaques in the hippocampal area of the brain.


Patent
Intelligent Synthetic Biology Center | Date: 2017-02-15

Provided are a food composition and a feed composition for removing amyloid plaques, each composition including ginsenoside F1, in which ginsenoside F1 is effective for removing amyloid plaques in the hippocampal area of the brain.


Patent
Korea Advanced Institute of Science, Technology and Intelligent Synthetic Biology Center | Date: 2012-12-24

The present invention relates to a novel uridine diphosphate (UDP)-glycosyltransferase, and particularly to a novel UDP-glycosyltransferase derived from ginseng and use thereof, a method for preparing glycosylated ginsenoside by converting protopanaxadiol (PPD)-type ginsenoside using the UDP-glycosyltransferase, a composition for converting the PPD-type ginsenoside into glycosylated ginsenoside, comprising the UDP-glycosyltransferase, a transformant or a culture thereof as active ingredients, a method for enhancing the expression of the UDP-glycosyltransferase using MeJA (methyl jasmonate), and a composition for enhancing the expression of the UDP-glycosyltransferase, which comprises MeJA as an active ingredient.


Patent
Korea Advanced Institute of Science, Technology and Intelligent Synthetic Biology Center | Date: 2013-10-16

The present invention provides an antimicrobial peptide polymer comprising at least one monomer which is digested by pepsin, a multimeric antimicrobial peptide complex comprising the polymer and a cell surface anchoring motif linked to the polymer, an antimicrobial microorganism displaying the multimeric antimicrobial peptide complex, an antimicrobial composition comprising the same, a method of treating an infectious disease caused by bacteria, yeast or fungi by administering the antimicrobial composition, and a method for producing the antimicrobial microorganism. According to the invention, living microorganisms displaying an antimicrobial peptide on the cell surface thereof may be administered in vivo without having to lyse the microbial cell and isolate and purify the antimicrobial peptide, so that the antimicrobial peptide exhibits antimicrobial activity. Thus, the antimicrobial peptide may be produced at significantly reduced costs so that it may have widespread use.


Patent
Korea Advanced Institute of Science, Technology and Intelligent Synthetic Biology Center | Date: 2012-12-24

The present invention relates to a novel uridine diphosphate (UDP)-glycosyltransferase, and particularly to a novel UDP-glycosyltransferase derived from ginseng and use thereof, a method for preparing glycosylated ginsenoside by converting protopanaxadiol (PPD)-type ginsenoside using the UDP-glycosyltransferase, a composition for converting the PPD-type ginsenoside into glycosylated ginsenoside, comprising the UDP-glycosyltransferase, a transformant or a culture thereof as active ingredients, a method for enhancing the expression of the UDP-glycosyltransferase using MeJA (methyl jasmonate), and a composition for enhancing the expression of the UDP-glycosyltransferase, which comprises MeJA as an active ingredient.


Patent
Korea Advanced Institute of Science, Technology and Intelligent Synthetic Biology Center | Date: 2016-03-23

Provided are a novel UDP-glycosyltransferase (uridine diphosphate glycosyltransferase) protein from Dolwoe (Gynostemma pentaphyllum) having glycosyltransfer activity for glucose linked by a glycosidic bond at the C-20 position of PPD (protopanaxadiol)-type or PPT (protopanaxatriol)-type ginsenoside, and use thereof.


The present invention relates to a pharmaceutical composition, a health functional food, and a feed composition for the prevention, improvement, or treatment of non-alcoholic liver disease or insulin resistance comprising ginsenoside F2. The pharmaceutical composition according to the present invention comprising ginsenoside F2 can inhibit the adipogenesis and lipid accumulation in the liver, improve insulin sensitivity, inhibit the expression of inflammatory cytokines such as TNF-, It-1, and IL-6 in the Kupffer cell, inhibit the expression of endocannabinoid synthase, thus capable of effectively preventing or treating non-alcoholic liver disease or insulin resistance.


Patent
Korea Advanced Institute of Science, Technology and Intelligent Synthetic Biology Center | Date: 2015-08-27

Provided are use of ginsenoside F2 in the prevention, improvement or treatment of liver disease, and a pharmaceutical composition, a health functional food, and a feed composition including ginsenoside F2. Ginsenoside F2 inhibits fat synthesis and accumulation in the liver, and increases distribution of regulatory T cells capable of inhibiting activity of inflammatory cells, thereby preventing hepatitis, and also increases expression of anti-inflammatory cytokine IL-10 in regulatory T cells, and inhibits differentiation of naive T cells into Th17 cells, and is thereby effectively used for the treatment of various liver diseases.


Patent
Korea Advanced Institute of Science, Technology and Intelligent Synthetic Biology Center | Date: 2016-03-02

The present invention relates to a pharmaceutical composition, a health functional food, and a feed composition for the prevention, improvement, or treatment of non-alcoholic liver disease or insulin resistance comprising ginsenoside F2. The pharmaceutical composition according to the present invention comprising ginsenoside F2 can inhibit the adipogenesis and lipid accumulation in the liver, improve insulin sensitivity, inhibit the expression of inflammatory cytokines such as TNF-, IL-, and IL-6 in the Kupffer cell, inhibit the expression of endocannabinoid synthase, thus capable of effectively preventing or treating non-alcoholic liver disease or insulin resistance.


Patent
Korea Advanced Institute of Science, Technology and Intelligent Synthetic Biology Center | Date: 2016-03-09

Provided are use of ginsenoside F2 in the prevention, improvement or treatment of liver disease, and a pharmaceutical composition, a health functional food, and a feed composition including ginsenoside F2. Ginsenoside F2 inhibits fat synthesis and accumulation in the liver, and increases distribution of regulatory T cells capable of inhibiting activity of inflammatory cells, thereby preventing hepatitis, and also increases expression of anti-inflammatory cytokine IL-10 in regulatory T cells, and inhibits differentiation of naive T cells into Th17 cells, and is thereby effectively used for the treatment of various liver diseases.

Loading Intelligent Synthetic Biology Center collaborators
Loading Intelligent Synthetic Biology Center collaborators